About: Middle East respiratory syndrome: current status and future prospects for vaccine development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Middle East respiratory syndrome: current status and future prospects for vaccine development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Middle East respiratory syndrome: current status and future prospects for vaccine development
Creator	Du, Lanying Jiang, Shibo
Source	Medline; PMC
abstract	The outbreaks of Middle East respiratory syndrome (MERS) previously in Middle East and recently in South Korea have raised serious concerns world-wide, reinforcing the importance of developing effective and safe vaccines against MERS-coronavirus (MERS-CoV). A number of vaccine candidates have been developed on the basis of viral vectors, recombinant proteins, DNAs, nanoparticles, and recombinant MERS-CoV, and some of them have shown efficacy in laboratory animals. However, the paucity of financial support has made it difficult to transfer effective candidates from the preclinical stage to clinical trials. Here, we summarize currently available MERS vaccine candidates and illustrate strategies for future development, with the aim of provoking government agencies and Big Pharma to invest more funds for developing efficacious and safe MERS vaccines.
has issue date	2015-09-28(xsd:dateTime)
bibo:doi	10.1517/14712598.2015.1092518
bibo:pmid	26414077
has license	bronze-oa
sha1sum (hex)	56503c049375713bf552b646d62b2cac38dee77e
schema:url	https://doi.org/10.1517/14712598.2015.1092518
resource representing a document's title	Middle East respiratory syndrome: current status and future prospects for vaccine development
has PubMed Central identifier	PMC4636333
has PubMed identifier	26414077
schema:publication	Expert Opinion on Biological Therapy
resource representing a document's body	covid:56503c049375713bf552b646d62b2cac38dee77e#body_text
is schema:about of	named entity 'vaccines' named entity 'Middle East respiratory syndrome' named entity 'raised' named entity 'reinforcing' named entity 'vaccine' named entity 'STATUS' named entity 'WIDE' named entity 'LABORATORY ANIMALS' named entity 'FUNDS' named entity 'MIDDLE EAST RESPIRATORY SYNDROME' named entity 'NANOPARTICLES' named entity 'CONCERNS' named entity 'MERS' named entity 'BIG' named entity 'NUMBER OF' named entity 'DIFFICULT' named entity 'EFFICACY' named entity 'FUTURE' named entity 'AVAILABLE' named entity 'CLINICAL TRIALS' named entity 'EFFECTIVE' named entity 'PREVIOUSLY' named entity 'MIDDLE EAST' named entity 'CURRENT' named entity 'HAVE' named entity 'VIRAL VECTORS' named entity 'DEVELOPMENT' named entity 'VACCINE DEVELOPMENT' named entity 'FUTURE' named entity 'WORLD' named entity 'STAGE' named entity 'AIM' named entity 'VACCINES' named entity 'RAISED' named entity 'RECOMBINANT PROTEINS' named entity 'HERE' named entity 'PRECLINICAL' named entity 'MERS VACCINE' named entity 'CORONAVIRUS' named entity 'SOUTH KOREA' named entity 'GOVERNMENT AGENCIES' named entity 'MERS-COV' named entity 'DNAS' named entity 'VACCINE' named entity 'FINANCIAL SUPPORT' named entity 'PROVOKING' named entity 'TO TRANSFER' named entity 'RECOMBINANT' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'CURRENTLY' named entity 'BASIS' named entity 'DEVELOPING' named entity 'OUTBREAKS' named entity 'SAFE' named entity 'STRATEGIES' named entity 'RECENTLY' named entity 'development' named entity 'laboratory animals' named entity 'South Korea' named entity 'candidates' named entity 'candidates' named entity 'Middle East' named entity 'candidates' named entity 'Middle East' named entity 'viral vectors' named entity 'MERS-CoV' named entity 'laboratory animals' named entity 'vaccine' named entity 'Big Pharma' named entity 'vaccine' named entity 'pre-clinical' named entity 'viruses' named entity 'vaccine' named entity 'MERS' named entity 'MERS' named entity 'protein' named entity '2, 3' named entity 'RBD' named entity 'virus entry' named entity 'rhesus macaques'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software